$ALZN

Alzamend Neuro, Inc.

Alzamend Neuro is a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. Its two licensed product candidates are AL001, an ionic cocrystal of lithium in human clinical development, and ALZN002, a patient-specific cell-based therapeutic vaccine for Alzheimer’s. AL001 is being studied for Alzheimer’s and the three psychiatric disorders; ALZN002 is intended to stimulate a patient’s immune system to target Alzheimer’s-related amyloid. Alzamend’s current business centers on research and clinical development rather than selling products. It plans to seek FDA marketing approval and commercialize the candidates through partnerships with biopharmaceutical companies and established distributors and producers, though it may sell products directly depending on market conditions. ALZN002’s Phase I/IIA trial is delayed, and the company does not expect to restart it until the first quarter of 2027. Alzamend is headquartered in Atlanta, Georgia.

0
2
2

No SEC Form 4 filings for $ALZN in the last 30 days.

See all $ALZN insider activity →
Low

Alzamend Neuro Presents Preliminary AL001 Brain Connectivity Findings

Alzamend Neuro presented preliminary fMRI findings comparing AL001 with lithium carbonate in six healthy participants. The study showed descriptive differences in brain connectivity, but no changes survived statistical correction. The company noted the small sample size and need for further study. The findings were presented at the Society for Neuroscience annual meeting on November 18, 2026, according to an SEC filing.

Alzamend Neuro, Inc. (ALZN): Regulation FD Disclosure

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 &' CTRU Lithium is considered a gold-standard treatment for bipolar I disorder, and is also used therapeutically in major depressive disorder, schizophrenia, Alzheimer's disease, and post-traumatic stress disorder. However, its clinical utility is constrained by a na

Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development

Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.

ALZN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning ALZN (Alzamend Neuro, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 2 bearish.

Recent ALZN coverage spans financial news, corporate actions and technology.

What's driving ALZN

  • Preliminary, small-sample neuroimaging readout with exploratory differences but no statistically robust connectivity effects.

    tradingview.com · Nov 18, 2026

  • The filing is a biotech scientific update, but it does not present new efficacy endpoints or regulatory milestones in the excerpt.

    SEC EDGAR 8-K · Nov 18, 2026

  • FDA feedback rejecting broader eligibility and steering toward efficacy and safety trials increases regulatory uncertainty and delays the BD development path.

    tradingview.com · Nov 17, 2026

  • FDA feedback forces a development-plan reset for AL001 in bipolar disorder, with BD Phase II likely ending and a Phase III efficacy and safety path pursued.

    SEC EDGAR 8-K · Nov 17, 2026

  • Early trial shows non‑significant trends favoring AL001 over inorganic lithium, suggesting potential clinical advantage.

    SEC EDGAR 8-K · Sep 29, 2026

AlphAI scores every news story that mentions ALZN with an AI model for sentiment and relevance, and aggregates insider trades from Alzamend Neuro, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ALZN

Score

Alzamend Neuro Presents Preliminary AL001 Brain Connectivity Findings

Alzamend Neuro presented preliminary fMRI findings comparing AL001 with lithium carbonate in six healthy participants. The study showed descriptive differences in brain connectivity, but no changes survived statistical correction. The company noted the small sample size and need for further study. The findings were presented at the Society for Neuroscience annual meeting on November 18, 2026, according to an SEC filing.

Alzamend Neuro, Inc. (ALZN): Regulation FD Disclosure

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 &' CTRU Lithium is considered a gold-standard treatment for bipolar I disorder, and is also used therapeutically in major depressive disorder, schizophrenia, Alzheimer's disease, and post-traumatic stress disorder. However, its clinical utility is constrained by a na

Alzamend Neuro Ends BD Trial SOW, Seeks FDA Guidance on AL001 Development

Alzamend Neuro terminated its bipolar disorder trial and related statement of work, receiving a $25,000 refund. The FDA advised against broader eligibility criteria, suggesting efficacy and safety trials for an NDA. The company plans to request FDA guidance for a revised plan, including a Phase III trial, and expects to announce trial results in December 2026 and FDA feedback by Q2 2027, according to an SEC filing.

$ALZNMedClinical / regulatory· discontinuation

In July 2024, Alzamend Neuro, Inc. entered into a Master Clinical Trial Agreement with The General Hospital Corporation d/b/a Massachusetts General Hospital…

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Information. As previously disclosed, in July 2024, Alzamend Neuro, Inc. (the “ Company ”) entered into a Master Clinical Trial Agreement (the “ Agreement ”) with The General Hospital Corporation d/b/a Massachusetts General Hospital (“ MGH ”) to conduct five Phase

$ALZNMedAI 8/10

Alzamend Neuro, Inc. (ALZN): Speaker Name: Ovidiu C. Andronesi I have the following financial interest or relationship to disclose with regard to the subject matter of this presentation :

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 DEPARTMENT OF RADIOLOGY Pharmacokinetics imaging of lithium at 7T – results from a phase 1/2A clinical trial with a novel organic lithium salt Massachusetts General Hospital HARVARD Medical School Ovidiu C. Andronesi , Katherine N. Maina, Daniel Park, May Aon, Shuqin

Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Alzamend Neuro (ALZN) announced it has regained compliance with Nasdaq's listing standards, meeting the minimum stockholders' equity requirement of $2.5M. The company reported $5.8M in equity as of July 31, 2026. This follows a previous non-compliance notice in March 2026, which the company addressed with a submitted plan. The CEO expressed focus on advancing clinical trials for AL001 in partnership with Massachusetts General Hospital.

Alzamend Neuro, Inc. Q1 2027: Net loss $3.03M, EPS $(0.68) — 10-Q Summary

Alzamend Neuro, Inc. reported a net loss of $3.03M for Q1 2027, up from $2.7M a year ago, with no revenue. Diluted net loss per share was $(0.68). The company advanced clinical trials for AL001 and ALZN002, with AL001 showing superior brain penetration compared to lithium carbonate. Partnerships with MGH/Harvard and Tesla Dynamic Coils supported Phase II imaging trials.

$ALZNMedOffering· $7.5M · closed

Alzamend Neuro, Inc. (ALZN): Entry into a Material Definitive Agreement

Alzamend Neuro, Inc. (ALZN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On July 31, 2026 (the “ Execution Date ”), Alzamend Neuro, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Agreement ”) with Ault Lending, LLC, a California limited liability

New bipolar trial scans how lithium reaches the brain at Mass General

Alzamend Neuro (Nasdaq: ALZN) has initiated a Phase II clinical trial for its AL001 drug candidate in patients with bipolar disorder type 1. Conducted at Massachusetts General Hospital, the study aims to assess how lithium is distributed in the brain and blood using advanced imaging techniques, comparing AL001 against traditional lithium carbonate. The goal is to optimize lithium delivery to the brain while minimizing systemic exposure to reduce side effects and potentially eliminate the need for frequent therapeutic drug monitoring.

Related tickers